ABBV Abbvie Inc

$ABBV $VKTX $ABBV headline data today on GUBRA amylin presentation. Someone probably will provide slides. But no details on all AEs and 4.4% placebo adjusted DC due to GI AE is not good for an amylin. It’s higher than what reported with leading incretins $LLY TZP and $VKTX 2735 Half life 10-12 days is C/W with what available out there from other mechanisms as CEO continues to mull combination ( which doesn’t seem to be a good idea with this amylin based on above )

$ABBV I at least added this yesterday, 274.94 ath. But made more mistakes yesterday than any day the last three months. So many false breakouts.

$ABBV What a monster stock this has been ... now consolidating over the base for potential next leg up

$ABBV $KURA $SNDX This is a hematologist prescriber survey embedded within the recent SNDX note, focused on NPM1 mutant AML (the largest subset of adult AML, ~30% of all AML). Core survey findings 1. Diagnosis & testing behavior Virtually all responding leukemia specialists now routinely test newly diagnosed AML patients for NPM1 mutation at baseline. Previously, many viewed revumenib only as a KMT2Ar drug; survey shows this perception has shifted after NPM1 label approval + real-world data. 2. Treatment preference for R/R NPM1 AML (already approved setting) ◦ Efficacy / deep MRD response is the #1 decision factor (ranked far above safety, oral convenience, or price). ◦ HCPs say revumenib’s ability to drive MRD negativity is its biggest differentiator vs older salvage regimens. ◦ Survey uptake expectation: Respondents expect Revuforj to capture a dominant share of eligible R/R NPM1 patients, even with competing menin inhibitor now on market.

$ABBV (AbbVie) gets FDA approval for tavapadon (brand name Juvmo), a once-daily pill for Parkinson's disease, with the drug acquired through AbbVie's 2023 purchase of Cerevel Therapeutics.

$ABBV (AbbVie) announces a multi-year collaboration with Iambic to accelerate AI-driven drug discovery in immunology, neuroscience, and oncology, leveraging Iambic's molecular superintelligence platform to shorten drug discovery timelines.

$ABBV I’ve just stubbornly held this since the spin out in 2013 collecting dividends and capital appreciation the entire way instead of trying to trade it like the day flippers and hedge funds. A good lesson for the kids out there!

$ABBV Epcoritamab + R-CHOP cut the risk of progression or death by 51% in frontline DLBCL. Phase 3 EPCORE DLBCL-2 topline, announced Monday: HR 0.49, p < 0.0001 at the first interim look, in newly diagnosed patients with IPI scores of 2 to 5. The data monitoring committee recommended unblinding the trial. The comparison is what makes it interesting. The only recent frontline challenger, Roche's Polivy + R-CHP, showed a 27% reduction in the POLARIX trial. This is roughly double that effect size, against a standard of care that has stood for about 25 years. Epcoritamab is already approved in 65+ countries for relapsed or refractory lymphoma. A frontline label moves the drug into the largest DLBCL population: newly diagnosed patients. The stock was up 1.6% Monday to 265.76. Genmab, the smaller co-developer, was up about 11%. Interim topline only: no overall survival data yet, detailed safety not disclosed. Full data at a future medical meeting is the next look.

$ABBV FRESH AFTER-HOURS SEC FILING: AbbVie updated its 2026 adjusted EPS guidance to $13.76–$13.96, versus the previously announced $13.87–$14.07 range. The change reflects approximately $216M of Q3 acquired IPR&D and milestone expense, which reduces adjusted EPS by about $0.11/share. Q3 adjusted EPS guidance is now $3.73–$3.77 versus $3.84–$3.88 previously. Important context: this is primarily an accounting impact from acquired R&D/milestone expense—not a newly disclosed deterioration in the underlying business. The 8-K was accepted by the SEC at 4:07 PM ET today, Oct. 5.

$ABBV Totally agree! I’ve held this for many years and love the divi. Ultra long term holder here.

$abbv Investment bank Wells Fargo set a 12-month price target for pharmaceutical company AbbVie of $300 on Thursday, giving the Chicago-based company an overweight rating, which is equivalent to a buy. Analyst Mohit Bansal said the AbbVie has solid patent protection for its core business units and that he is expecting updates on the firm’s work in oncology and neuroscience. “We rate ABBV Overweight, as we think that the stock is reasonably priced for strong growth into the next decade, coupled with long-term patent protection for key businesses. We expect mid-stage pipeline to come to limelight in next 12 months, which should help with multiple expansion,” https://www.cnbc.com/2026/09/10/stock-market-today-live-updates.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension

What are your favorite #stocks for #investing related to #aging? #babyboomers $ABBV $REGN $NVS $VOO I like #OutlookTherapeutics. #healthcare #eyecare

$ABBV Beast of a stock when not being grossly manipulated by the fraud hedge funds and market makers.

$ABBV case watch: a June class action alleges AbbVie's Juvederm fillers can cause delayed granulomas, hard lumps appearing months or years after injection, without adequate warning. Complaint stage, nothing to claim. Open Class Actions.

$ABBV FDA approved tavapadon Friday, a once-a-day Parkinson's pill AbbVie will sell as Juvmo. The one-level-down point: this is the 8.7 billion dollar Cerevel acquisition starting to pay off. AbbVie bought Cerevel in 2023 largely for the neuroscience pipeline; tavapadon is the first approval to come out of it. Parkinson's affects more than 11 million people worldwide. The drug mimics dopamine, the brain chemical the disease depletes. Trial side effects were mostly nausea, dizziness, and headache. The commercial question is Medicare. Citi had expected a third-quarter 2026 launch with gradual uptake while coverage negotiations play out. AbbVie is targeting more than 5 billion in combined Parkinson's sales.

Top 3 #momentum #stocks In The GorillaTrades #portfolio This Week: AbbVie $ABBV +3.3%, Harmony Biosciences $HRMY +3.2% , and Descartes Systems $DSGX +2.9%

$ABBV AbbVie Named Official Pharmaceutical Sponsor of the PGA TOUR and 2026 Presidents Cup, Launches Birdies for Brain Health Campaign Wake me up under $250 !!